Share on StockTwits

Idenix Pharmaceuticals (NASDAQ:IDIX) announced its earnings results on Thursday. The company reported ($0.43) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.21) by $0.22, reports.

Several analysts have recently commented on the stock. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Idenix Pharmaceuticals in a research note on Tuesday, June 10th. They now have a $5.00 price target on the stock, down previously from $24.50. On a related note, analysts at JMP Securities upgraded shares of Idenix Pharmaceuticals to a “market perform” rating in a research note on Monday, June 9th. Finally, analysts at Robert W. Baird upgraded shares of Idenix Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Monday, June 9th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Idenix Pharmaceuticals currently has an average rating of “Hold” and an average price target of $5.00.

Shares of Idenix Pharmaceuticals (NASDAQ:IDIX) traded down 0.12% on Thursday, hitting $24.42. 1,409,786 shares of the company’s stock traded hands. Idenix Pharmaceuticals has a 52-week low of $2.93 and a 52-week high of $24.45. The stock’s 50-day moving average is $24.09 and its 200-day moving average is $11.27. The company’s market cap is $3.684 billion.

Idenix Pharmaceuticals, Inc (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.